

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3885720
<b>Application Number:</b>	10828419
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	5347
<b>Title of Invention:</b>	Pharmaceutical compositions of atorvastatin
<b>First Named Inventor/Applicant Name:</b>	Alfred Berchielli
<b>Customer Number:</b>	28880
<b>Filer:</b>	J. Michael Dixon/Kelly Smith
<b>Filer Authorized By:</b>	J. Michael Dixon
<b>Attorney Docket Number:</b>	PC25684A
<b>Receipt Date:</b>	04-SEP-2008
<b>Filing Date:</b>	20-APR-2004
<b>Time Stamp:</b>	11:49:42
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$640
RAM confirmation Number	7332
Deposit Account	161445
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Extension of Time	PC25684A-Petition_Ext_Time.pdf	34244 f91181bcc19688d011120e8ca0fe16a2b797509	no	1
Warnings:					
Information:					
2		PC25684A-Amendment.pdf	264636 7e4828002e15c56212aeb0e3c5e44973b0916dc	yes	9
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment - After Non-Final Rejection		1	1	
	Claims		2	5	
	Applicant Arguments/Remarks Made in an Amendment		6	9	
Warnings:					
Information:					
3	Information Disclosure Statement Letter	PC25684A-IDS.pdf	36476 86c1ce48662be7e757281425d8b07262c4e1563	no	1
Warnings:					
Information:					
4	1.501 Submission by Patent Owner	PC25684A-IDS_Citation.pdf	31178 d335c3ba8e1b0c1c51e84a95d37989f9c133491	no	1
Warnings:					
Information:					
5	NPL Documents	PC25684A-Pharmaceutical_Research.pdf	938191 b3566236d28808f56c70758bd121914b0c339669	no	5
Warnings:					
Information:					
6	Fee Worksheet (PTO-06)	fee-info.pdf	31962 78ca9198b2157387d1646d6fb78c4a62685d802	no	2
Warnings:					

<b>Information:</b>	
<b>Total Files Size (in bytes):</b>	1336687
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b></p> <p>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b></p> <p>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b></p> <p>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>	